The importance of more research on cancer is increasingly becoming obvious. Researchers using the Surveillance, Epidemiology, and End Result (SEER) data, sought to determine the prior cancer prevalence rates among cancer survivors. The study revealed that quite a significant number of cancer survivors are diagnosed with a second type of cancer. The prior prevalence rates were higher for individuals above 65 years of age where 25 percent of survivors were affected. For younger adults who are below 65 years of age, the prevalence rates were a bit lower at 11 percent. Of the overall population of 740990 cases detected between January 2009 and December 2013, 141021 cases were confirmed second order cancer cases.
The research also revealed that most cancer survivors could be facing exclusion from the off early cancer detection mechanism. The evidence also proved that they do not feature in clinical trials and are extremely underrepresented in observational research. This eventually leads to little information that guides structuring of treatment procedures and other survival needs for the patients. Better analysis of data on this patients will enhance the generalizability of treatment, patient experience, and positive treatment outcomes.
It is this disconnect between clinical procedures and the available patient data that has hindered the development of patient-specific treatments. Tempus hopes to bridge that gap and bury the problem in history. Cofounded by Eric Lefkofsky, Tempus has developed a technological platform that helps doctors, clinicians, and researchers alike to make decent data determined treatment decisions. The technology analyzes the patient genetic code and then applies advanced genomic sequencing analytical tools to assist doctors in making patient-centric decisions.
Eric Lefkofsky, who remains passionate about using data to recommend patient-specific treatments, has assembled a great team at Tempus. The organization has partnered with various cancer centers to achieve their objective. Aside from the Tempus project, Eric Lefkofsky is a remarkable philanthropist. He has made charitable contributions to various institutions involved in cancer research. Some of the institutions that have benefited from Eric Lefkofsky’s donations include the University of Michigan for cancer research, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, and New York’s Weill Cornell Medicine for breast cancer research.